Short answer
Gilead Sciences (GILD) filed an 8-K current report with the SEC on October 29, 2026 reporting Item EX-99.1 (Exhibit EX-99.1), Item 2.02 (Results of Operations and Financial Condition). Gilead announced third-quarter 2026 results for the period ended September 30, 2026.
Gilead Sciences 8-K event analysis
AI summary of each reported item and its exhibits
Item 2.02 · Results of Operations and Financial Condition
- Gilead announced third-quarter 2026 results for the period ended September 30, 2026
- Full financial results and GAAP-to-non-GAAP reconciliations available in Exhibit 99.1
- Investors should distinguish management’s non-GAAP measures from GAAP results when assessing performance
Item EX-99.1 · Exhibit EX-99.1
- Q3 product sales $8.3B, up 13%; excluding Veklury, sales rose 16% to $8.2B, showing strong underlying growth
- HIV sales increased 18% to $6.2B, led by Biktarvy sales up 10% to $4.1B
- Trodelvy sales rose 42% to $506M, while Cell Therapy sales fell 18% to $355M from competitive pressure
- GAAP diluted EPS declined to $1.94 from $2.43, but non-GAAP EPS increased to $2.55 from $2.47
- 2026 product-sales guidance raised to $31.0B-$31.3B, while full-year loss guidance worsened from $9.88B acquired IPR&D charges tied to acquisitions
Generated from the filing text and exhibits; verify against the original. What 8-K item codes mean
Other Gilead Sciences 8-K filings
Get the next GILD 8-K as it lands
Follow GILD for push alerts, or ask the research agent what this filing means.